(PharmaNewsWire.Com, August 16, 2017 ) Psoriatic arthritis is a chronic inflammatory disease that affects the distal joints in the body and may also affect the back and sacroiliac joints of the pelvis. The global market for psoriatic arthritis is expected to witness moderate growth during the forecast period and factors like the increase in penetration of biologic therapies are expected to augment the prospects for growth in this market. Additionally, the recent launch of products like Otezla and Stelara is also expected to boost market growth during the forecast period, resulting in its moderate CAGR of nearly 5% by 2019.
In this market research report, Publisher analysts estimate the Americas to account for more than 40% of the total market share by 2019. High market dominion of this region can be attributed to factors such as the increase in public awareness and the growing preference for biologic drugs.
Segmentation by mechanism of action and analysis of: TNF inhibitors, PDE4 inhibitors, & interleukin blockers The TNF inhibitors aid in suppressing the inflammatory response in the patient's body. These inhibitors are used to manage diseases like rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, and seronegative spondyloarthropathies. Moreover, its ability to use a targeted mechanism to treat most of the inflammatory and autoimmune diseases is primarily responsible for its high market share of almost 80% by 2019.
The report offers an analysis of each of the following segments and discusses its impact on the overall market growth - - TNF inhibitors - PDE4 inhibitors - Interleukin blockers - Others
Segmentation by type of disease and analysis of: mild, moderate, & severe psoriatic arthritis The mild psoriatic arthritis segment accounts for more than 60% of all the diagnosed cases and is the most common type of psoriatic arthritis in patients across the globe. This condition affects less than four joints in the body and is also known as oligoarticular arthritis.
The report offers an analysis of each of the following segments and discusses its impact on the overall market growth - - Mild psoriatic arthritis - Moderate psoriatic arthritis - Severe psoriatic arthritis
Competitive landscape and key vendors: Abbvie, Amgen, Janssen Pharmaceuticals This market is primarily dominated by large vendors due to their extensive product portfolios. The company that manufactures and markets a drug that can treat psoriatic arthritis, and also exhibit a high safety and efficacy profile, is expected to gain a competitive advantage over its rivals during the forecast period.
Leading vendors in this market are - - Abbvie - Amgen - Janssen Pharmaceuticals - Celgene - UCB
Other prominent vendors analyzed in this market study are Alder Biopharmaceuticals, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hofffmann-La Roche, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and Takeda Pharmaceutical.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
